DeepMed Research

Nepafenac

Generic Name: Nepafenac

Brand Names: Ilevro, Nevanac

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O_₂

CAS Number: 78281-72-8

Unique Ingredient Identifier: 0J9L7J6V8C

Background: Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Indication: For the treatment of pain and inflammation associated with cataract surgery.

Associated Conditions: Inflammation, Pain

Clinical Trials

Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy

Not Applicable

Conditions: Glaucoma, Closed-Angle
Glaucoma, Narrow-Angle
Glaucoma, Angle-Closure

Interventions: Drug: Dexamethasone Disodium Phosphate 0.1%
Drug: Nepafenac 0.1%
Drug: Hydroxyethylcellulose 0.19%

First Posted Date: 2016-11-04

Last Posted Date: 2018-04-24

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 100

Registration Number: NCT02955641

Locations: 🇮🇱
Sheba Medical Center, Tel HaShomer, Israel

Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: Nepafenac Eye Drops
Drug: Placebo (Artificial Tears)

First Posted Date: 2016-07-01

Last Posted Date: 2017-05-05

Lead Sponsor: University Hospital of Patras

Target Recruit Count: 55

Registration Number: NCT02821390

Locations: 🇬🇷
University Hospital of Patras, Patras, Achaea, Greece

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Not Applicable

Completed

Conditions: Cataract

Interventions: Drug: nepafenac 0.3%
Drug: ketorolac

First Posted Date: 2016-04-27

Last Posted Date: 2017-03-07

Lead Sponsor: MDbackline, LLC

Target Recruit Count: 200

Registration Number: NCT02752646

Locations: 🇺🇸
Cincinnati Eye Institute, Edgewood, Kentucky, United States
🇺🇸
Harvard Eye Associates, Laguna Hills, California, United States

Dropless vs. Standard Drops Contralateral Eye Study

Phase 4

Completed

Conditions: Cataract

Interventions: Drug: TriMoxiVanc
Drug: Moxifloxacin HCl 0.5%
Drug: Ilevro
Drug: Prednisolone acetate 1%

First Posted Date: 2015-08-04

Last Posted Date: 2018-02-23

Lead Sponsor: Carolina Eyecare Physicians, LLC

Target Recruit Count: 59

Registration Number: NCT02515045

Locations: 🇺🇸
Associated Eye Care, Stillwater, Minnesota, United States
🇺🇸
Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States
🇺🇸
Minnesota Eye Consultants, P.A., Bloomington, Minnesota, United States

and more 1 locations

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

Not Applicable

Conditions: Post Surgical Management
Pain Management
Inflamation Management

Interventions: Drug: Diclofenac
Drug: Nepafenac

First Posted Date: 2015-07-23

Last Posted Date: 2015-07-24

Lead Sponsor: Wolfson Medical Center

Target Recruit Count: 30

Registration Number: NCT02506348

Locations: 🇮🇱
The E.Wolfson Medical Center, Holon, Israel

NSAIDs and PGE2 Levels in Vitrectomy Patients

Phase 3

Completed

Conditions: Vitreous Inflammation

Interventions: Drug: Indomethacin 0.5% eyedrops
Drug: Nepafenac 0.1% eyedrops
Drug: Bromfenac 0.09% eyedrops
Drug: Ketorolac 0.5% eyedrops

First Posted Date: 2015-02-12

Last Posted Date: 2015-02-12

Lead Sponsor: Università degli Studi di Brescia

Target Recruit Count: 70

Registration Number: NCT02361645

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification

Phase 4

Completed

Conditions: Cystoid Macular Edema
Cataract

Interventions: Drug: Nepafenac
Drug: Ketorolac

First Posted Date: 2014-03-12

Last Posted Date: 2014-03-12

Lead Sponsor: Hospital Oftalmologico de Brasilia

Target Recruit Count: 40

Registration Number: NCT02084576

Locations: 🇧🇷
Hospital Oftalmologico de Brasília, Brasilia, DF, Brazil

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes

Phase 4

Completed

Conditions: Intraocular Pressure

Interventions: Drug: nepafenac

First Posted Date: 2013-11-27

Last Posted Date: 2013-11-27

Lead Sponsor: Dr T V Patel Eye Institute

Target Recruit Count: 327

Registration Number: NCT01995890

Locations: 🇮🇳
Dr TV Patel Eye Insititute, Vadodara, Gujarat, India

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Phase 4

Terminated

Conditions: Uveitis
Macular Edema

Interventions: Drug: Nepafenac
Drug: Difluprednate
Drug: Prednisolone acetate

First Posted Date: 2013-09-11

Last Posted Date: 2021-01-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT01939691

Locations: 🇮🇳
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India

Nepafenac Once Daily for Macular Edema - Study 2

Phase 3

Completed

Conditions: Non-Proliferative Diabetic Retinopathy
Cataract

Interventions: Other: Vehicle
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Drug: Prednisolone acetate

First Posted Date: 2013-06-07

Last Posted Date: 2016-08-02

Lead Sponsor: Alcon Research

Target Recruit Count: 819

Registration Number: NCT01872611

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy